Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

29.65
+0.15000.51%
Volume:1.49M
Turnover:44.08M
Market Cap:5.11B
PE:13.50
High:29.78
Open:29.50
Low:29.15
Close:29.50
52wk High:30.96
52wk Low:19.69
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.95
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:3.91
PE(LYR):12.89

Loading ...

ACADIA Pharmaceuticals appoints Jonathan M. Poole to board and audit committee

Reuters
·
Mar 05

ACADIA Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Mar 05

U.S. RESEARCH ROUNDUP-CrowdStrike, Oracle, Vulcan Materials

Reuters
·
Mar 04

ACADIA Pharmaceuticals Inc : JP Morgan Raises Target Price to $34 From $31

THOMSON REUTERS
·
Mar 04

ACADIA Pharmaceuticals Appoints Jonathan M. Poole to Board of Directors

Reuters
·
Mar 04

BUZZ-Australia's Neuren Pharmaceuticals drops as US partner seeks EMA re-examination

Reuters
·
Mar 03

European Regulators Recommend Against Acadia's Application for Rett Syndrome Treatment

Dow Jones
·
Mar 03

EMA CHMP Issues Negative Opinion on Acadia Trofinetide for Rett Syndrome

Reuters
·
Mar 03

Stock Track | ACADIA Pharmaceuticals Plummets 7.37% Intraday on Negative CHMP Opinion for Trofinetide

Stock Track
·
Mar 03

ACADIA Pharmaceuticals Announces Plan to Request Re-Examination Following Negative Chmp Opinion for Trofinetide for the Treatment of Rett Syndrome

THOMSON REUTERS
·
Mar 03

ACADIA Pharmaceuticals Charts Growth Path After Record Year

TIPRANKS
·
Mar 02

ACADIA Pharmaceuticals' Rett Syndrome Drug Faces EMA Setback

MT Newswires Live
·
Feb 27

Ema's Chmp: Committee Recommended Not Granting Marketing Authorisation for Daybu (Trofinetide)

THOMSON REUTERS
·
Feb 27

AcadeMedia Expands Share Capital After Warrant Exercise

TIPRANKS
·
Feb 27

ACADIA Pharmaceuticals Is Maintained at Hold by Stifel

Dow Jones
·
Feb 26

ACADIA Pharmaceuticals (ACAD) Receives a Buy from Needham

TIPRANKS
·
Feb 26

Morgan Stanley Lifts Price Target on ACADIA Pharmaceuticals to $26 From $25, Keeps Equalweight Rating

MT Newswires Live
·
Feb 26

A Look At ACADIA Pharmaceuticals (ACAD) Valuation After A 29.11% One Year Total Return

Simply Wall St.
·
Feb 26

Stock Track | ACADIA Pharmaceuticals Plummets 6.49% in Pre-Market Following Quarterly Revenue Shortfall

Stock Track
·
Feb 26

ACADIA Pharmaceuticals: Accelerating Commercial Momentum and Expanded Outlook Support Raised Price Target and Buy Rating

TIPRANKS
·
Feb 26